GlassScriptPhysician profile
Andrew S Boxer
NPI 1225294499
$67,277.58
in general payments reported to CMS, 2019-2025
26 companies · $6,759 in 2025
The $6,759 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $7,679 · 2021: $6,038 · 2022: $6,650 · 2023: $8,050 · 2024: $14K · 2025: $6,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,825.00 |
| Food and Beverage | $1,565.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,332.89 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Allergan, INC. | $18,960.78 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $10,093.51 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $7,903.52 | 2024-2025 | Voquezna |
| Shionogi INC | $5,999.55 | 2019 | |
| Pfizer INC. | $205.91 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.72 | 2019-2024 | Xifaxan |
| Celgene Corporation | $99.11 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $57.76 | 2019-2023 | Stelara |
| Merck Sharp & Dohme LLC | $57.49 | 2021-2022 | |
| Madrigal Pharmaceuticals | $53.71 | 2025 | Rezdiffra |
| Irhythm Technologies, INC. | $42.04 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.45 | 2019-2025 | Gattex |
| Laborie Medical Technologies Corp. | $35.21 | 2023 | |
| Qol Medical, LLC | $34.71 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $26.60 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $25.42 | 2020-2021 | |
| Ardelyx, INC. | $25.28 | 2022 | |
| Ucb, INC. | $25.00 | 2019 | |
| Braintree Laboratories, INC. | $24.87 | 2021-2023 | Sutab |
| Amgen INC. | $20.93 | 2021 | |
| Ethicon US, LLC | $15.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.52 | 2023 | Dupixent |
| Gilead Sciences, INC. | $13.64 | 2019 | |
| Boston Scientific Corporation | $13.19 | 2023 | Watchman |
| Ferring Pharmaceuticals INC. | $12.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Boxer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.